Annual Guidance of $178 - $182 Million in Revenue and $38 - $42 Million of Adjusted EBITDA, Representing Year-Over-Year Increase of 13% in Revenues and 19% in Adjusted EBITDA Based on ...
"We believe that 2025 will be a pivotal year for SELLAS as we continue to advance our clinical stage portfolio of novel therapeutics for hematologic malignancies,” said Angelos ...
The IED blast in Chhattisgarh on Monday might seem like a sign that the potency of the CPI(Maoist) in inflicting such acts remains, but these are also the acts of a flailing outfit ...